Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Shares Outstanding (2016 - 2025)

Ocular Therapeutix has reported Shares Outstanding over the past 13 years, most recently at $215.9 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $215.9 million for Q4 2025, up 36.88% from a year ago — trailing twelve months through Dec 2025 was $215.9 million (up 36.88% YoY), and the annual figure for FY2025 was $215.9 million, up 36.88%.
  • Shares Outstanding for Q4 2025 was $215.9 million at Ocular Therapeutix, up from $174.9 million in the prior quarter.
  • Over the last five years, Shares Outstanding for OCUL hit a ceiling of $215.9 million in Q4 2025 and a floor of $76.2 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $79.3 million (2023), compared with a mean of $115.6 million.
  • Biggest five-year swings in Shares Outstanding: increased 0.53% in 2022 and later soared 99.58% in 2024.
  • Ocular Therapeutix's Shares Outstanding stood at $76.7 million in 2021, then rose by 0.61% to $77.2 million in 2022, then surged by 48.91% to $115.0 million in 2023, then surged by 37.22% to $157.7 million in 2024, then soared by 36.88% to $215.9 million in 2025.
  • The last three reported values for Shares Outstanding were $215.9 million (Q4 2025), $174.9 million (Q3 2025), and $172.9 million (Q2 2025) per Business Quant data.